101
|
Srinivasan A. Experimental inhibition of peptide fibrillogenesis by synthetic peptides, carbohydrates and drugs. Subcell Biochem 2012; 65:271-94. [PMID: 23225008 DOI: 10.1007/978-94-007-5416-4_12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Peptide fibrillogenesis generally begins by the transformation of normally soluble proteins into elongated aggregates which are called as amyloid. These fibrils mainly consist of ß-sheets. They share certain common characteristics such as a cross-ß x-ray diffraction pattern, association with other common proteins and typical staining by the dye Congo Red. The individual form of the deposit consists of a disease-specific peptide/protein. The disease-specific protein serves as the basis for the classification of the amyloids. The association of fibril-forming peptides/proteins with diseases makes them primary disease-targets. Understanding the molecular interactions involved in the fibril formation becomes the foremost requirement to characterize the target. Interference with these interactions of ß-sheets in vitro prevents and sometimes reverses the fibril assembly. A small molecule capable of interfering with the formation of fibril could have therapeutic applications in these diseases. This anti-aggregation approach appears to be a viable treatment option. A search for such a molecule is pursued actively world over. All types of compounds and approaches to slow down or prevent the aggregation process have been described in the literature. These efforts are reviewed in this chapter.
Collapse
|
102
|
Effect ofN-homocysteinylation on physicochemical and cytotoxic properties of amyloid β-peptide. FEBS Lett 2011; 586:127-31. [DOI: 10.1016/j.febslet.2011.12.018] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2011] [Revised: 11/30/2011] [Accepted: 12/14/2011] [Indexed: 12/20/2022]
|
103
|
Klein JJ, Hecht S. Synthesis of a New Class of Bis(thiourea)hydrazide Pseudopeptides as Potential Inhibitors of β-Sheet Aggregation. Org Lett 2011; 14:330-3. [DOI: 10.1021/ol203074p] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Jan J. Klein
- Department of Chemistry, Humboldt-Universität zu Berlin, 12489 Berlin, Germany
| | - Stefan Hecht
- Department of Chemistry, Humboldt-Universität zu Berlin, 12489 Berlin, Germany
| |
Collapse
|
104
|
Beheshti S, Martić S, Kraatz HB. Electrochemical “Signal-On” Reporter for Amyloid Aggregates. Chemphyschem 2011; 13:542-8. [DOI: 10.1002/cphc.201100728] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2011] [Indexed: 11/10/2022]
|
105
|
Sundaram RK, Kasinathan C, Stein S, Sundaram P. Novel Detox Gel Depot sequesters β-Amyloid Peptides in a mouse model of Alzheimer's Disease. Int J Pept Res Ther 2011; 18:99-106. [PMID: 22712003 DOI: 10.1007/s10989-011-9283-7] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
Abstract
Alzheimer's Disease (AD), a debilitating neurodegenerative disease is caused by aggregation and accumulation of a 39-43 amino acid peptide (amyloid β or Aβ) in brain parenchyma and cerebrovasculature. The rational approach would be to use drugs that interfere with Aβ-Aβ interaction and disrupt polymerization. Peptide ligands capable of binding to the KLVFF (amino acids 16-20) region in the Aβ molecule have been investigated as possible drug candidates. Retro-inverso (RI) peptide of this pentapeptide, ffvlk, has been shown to bind artificial fibrils made from Aβ with moderate affinity. We hypothesized that a 'detox gel', which is synthesized by covalently linking a tetrameric version of RI peptide ffvlk to poly (ethylene glycol) polymer chains will act like a 'sink' to capture Aβ peptides from the surrounding environment. We previously demonstrated that this hypothesis works in an in vitro system. The present study extended this hypothesis to an in vivo mouse model of Alzheimer's Disease and determined the therapeutic effect of our detox gel. We injected detox gel subcutaneously to AD model mice and analyzed brain levels of Aβ-42 and improvement in memory parameters. The results showed a reduction of brain amyloid burden in detox gel treated mice. Memory parameters in the treated mice improved. No undesirable immune response was observed. The data strongly suggest that our detox gel can be used as an effective therapy to deplete brain Aβ levels. Considering recent abandonment of failed antibody based therapies, our detox gel appears to have the advantage of being a non-immune based therapy.
Collapse
Affiliation(s)
- Ranjini K Sundaram
- Recombinant Technologies LLC, 1090 Meriden Waterbury Road, Suite 1, Cheshire, CT 06410
| | | | | | | |
Collapse
|
106
|
Krištofiková Z, Kříž Z, Řípová D, Koča J. Interactions of Amyloid β Peptide 1–40 and Cerebrosterol. Neurochem Res 2011; 37:604-13. [DOI: 10.1007/s11064-011-0650-8] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2011] [Revised: 10/31/2011] [Accepted: 11/03/2011] [Indexed: 01/07/2023]
|
107
|
A peptide that binds specifically to the β-amyloid of Alzheimer's disease: selection and assessment of anti-β-amyloid neurotoxic effects. PLoS One 2011; 6:e27649. [PMID: 22102917 PMCID: PMC3213187 DOI: 10.1371/journal.pone.0027649] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2011] [Accepted: 10/21/2011] [Indexed: 11/24/2022] Open
Abstract
The accumulation of the amyloid-β peptide (Aβ) into amyloid plaques, an essential event in Alzheimer's disease (AD) pathogenesis, has caused researchers to seek compounds that physiologically bind Aβ and modulate its aggregation and neurotoxicity. In order to develop new Aβ-specific peptides for AD, a randomized 12-mer peptide library with Aβ1-10 as the target was used to identify peptides in the present study. After three rounds of selection, specific phages were screened, and their binding affinities to Aβ1-10 were found to be highly specific. Finally, a special peptide was synthesized according to the sequences of the selected phages. In addition, the effects of the special peptide on Aβ aggregation and Aβ-mediated neurotoxicity in vitro and in vivo were assessed. The results show that the special peptide not only inhibited the aggregation of Aβ into plaques, but it also alleviated Aβ-induced PC12 cell viability and apoptosis at appropriate concentrations as assessed by the cell counting kit-8 assay and propidium iodide staining. Moreover, the special peptide exhibited a protective effect against Aβ-induced learning and memory deficits in rats, as determined by the Morris water maze task. In conclusion, we selected a peptide that specifically binds Aβ1-10 and can modulate Aβ aggregation and Aβ-induced neuronal damage. This opens up possibilities for the development of a novel therapeutic approach for the treatment of AD.
Collapse
|
108
|
Abstract
Alzheimer's disease (AD) is a common neurodegenerative disorder characterized by the deposition of amyloids in the brain. One prominent form of amyloid is composed of repeating units of the amyloid-β (Aβ) peptide. Over the past decade, it has become clear that these Aβ amyloids are not homogeneous; rather, they are composed of a series of structures varying in their overall size and shape and the number of Aβ peptides they contain. Recent theories suggest that these different amyloid conformations may play distinct roles in disease, although their relative contributions are still being discovered. Here, we review how chemical probes, such as Congo red, thioflavin T and their derivatives, have been powerful tools for the better understanding of amyloid structure and function. Moreover, we discuss how design and deployment of conformationally selective probes might be used to test emerging models of AD.
Collapse
Affiliation(s)
- Ashley A Reinke
- Department of Biological Chemistry, Pathology and the Life Sciences Institute, University of Michigan, Ann Arbor, MI 48109-2216, USA
| | | |
Collapse
|
109
|
Brambilla D, Le Droumaguet B, Nicolas J, Hashemi SH, Wu LP, Moghimi SM, Couvreur P, Andrieux K. Nanotechnologies for Alzheimer's disease: diagnosis, therapy, and safety issues. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 2011; 7:521-40. [PMID: 21477665 DOI: 10.1016/j.nano.2011.03.008] [Citation(s) in RCA: 171] [Impact Index Per Article: 13.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/07/2011] [Revised: 03/07/2011] [Accepted: 03/22/2011] [Indexed: 12/14/2022]
Abstract
Alzheimer's disease (AD) represents the most common form of dementia worldwide, affecting more than 35 million people. Advances in nanotechnology are beginning to exert a significant impact in neurology. These approaches, which are often based on the design and engineering of a plethora of nanoparticulate entities with high specificity for brain capillary endothelial cells, are currently being applied to early AD diagnosis and treatment. In addition, nanoparticles (NPs) with high affinity for the circulating amyloid-β (Aβ) forms may induce "sink effect" and improve the AD condition. There are also developments in relation to in vitro diagnostics for AD, including ultrasensitive NP-based bio-barcodes, immunosensors, as well as scanning tunneling microscopy procedures capable of detecting Aβ(1-40) and Aβ(1-42). However, there are concerns regarding the initiation of possible NP-mediated adverse events in AD, thus demanding the use of precisely assembled nanoconstructs from biocompatible materials. Key advances and safety issues are reviewed and discussed.
Collapse
Affiliation(s)
- Davide Brambilla
- Laboratoire de Physico-Chimie, Pharmacotechnie et Biopharmacie, Univ Paris-Sud, Faculté de Pharmacie, Châtenay-Malabry, France
| | | | | | | | | | | | | | | |
Collapse
|
110
|
Sakurai T, Iwasaki T, Okuno T, Kawata Y, Kise N. Evaluation of Aβ fibrillization inhibitory effect by a PEG-peptide conjugate based on an Aβ peptide fragment with intramolecular FRET. Chem Commun (Camb) 2011; 47:4709-11. [PMID: 21416107 DOI: 10.1039/c0cc05668e] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
A PEG-peptide conjugate based on an amyloid β peptide fragment was synthesized. The formed amyloid protofibril-like aggregates induced intramolecular FRET. It proved to be useful as a bioprobe to evaluate the inhibitory effect of organic molecules toward amyloid fibrillization.
Collapse
Affiliation(s)
- Toshihiko Sakurai
- Department of Chemistry and Biotechnology, Graduate School of Engineering, Tottori University, 4-101 Koyama-chou, Tottori 680-8552, Japan.
| | | | | | | | | |
Collapse
|
111
|
Ito M, Johansson J, Strömberg R, Nilsson L. Unfolding of the amyloid β-peptide central helix: mechanistic insights from molecular dynamics simulations. PLoS One 2011; 6:e17587. [PMID: 21408230 PMCID: PMC3049775 DOI: 10.1371/journal.pone.0017587] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2010] [Accepted: 02/05/2011] [Indexed: 11/18/2022] Open
Abstract
Alzheimer's disease (AD) pathogenesis is associated with formation of amyloid fibrils caused by polymerization of the amyloid β-peptide (Aβ), which is a process that requires unfolding of the native helical structure of Aβ. According to recent experimental studies, stabilization of the Aβ central helix is effective in preventing Aβ polymerization into toxic assemblies. To uncover the fundamental mechanism of unfolding of the Aβ central helix, we performed molecular dynamics simulations for wild-type (WT), V18A/F19A/F20A mutant (MA), and V18L/F19L/F20L mutant (ML) models of the Aβ central helix. It was quantitatively demonstrated that the stability of the α-helical conformation of both MA and ML is higher than that of WT, indicating that the α-helical propensity of the three nonpolar residues (18, 19, and 20) is the main factor for the stability of the whole Aβ central helix and that their hydrophobicity plays a secondary role. WT was found to completely unfold by a three-step mechanism: 1) loss of α-helical backbone hydrogen bonds, 2) strong interactions between nonpolar sidechains, and 3) strong interactions between polar sidechains. WT did not completely unfold in cases when any of the three steps was omitted. MA and ML did not completely unfold mainly due to the lack of the first step. This suggests that disturbances in any of the three steps would be effective in inhibiting the unfolding of the Aβ central helix. Our findings would pave the way for design of new drugs to prevent or retard AD.
Collapse
Affiliation(s)
- Mika Ito
- Department of Biosciences and Nutrition, Karolinska Institutet, Huddinge, Sweden
| | - Jan Johansson
- Department of Anatomy, Physiology and Biochemistry, Swedish University of Agricultural Sciences, the Biomedical Centre, Uppsala, Sweden
- Department of Neurobiology, Care Sciences and Society (NVS), Karolinska Institutet Alzheimer Disease Research Center (KI-ADRC), Huddinge, Sweden
| | - Roger Strömberg
- Department of Biosciences and Nutrition, Karolinska Institutet, Huddinge, Sweden
| | - Lennart Nilsson
- Department of Biosciences and Nutrition, Karolinska Institutet, Huddinge, Sweden
- * E-mail:
| |
Collapse
|
112
|
Bett CK, Serem WK, Fontenot KR, Hammer RP, Garno JC. Effects of peptides derived from terminal modifications of the aβ central hydrophobic core on aβ fibrillization. ACS Chem Neurosci 2010; 1:661-78. [PMID: 22778807 DOI: 10.1021/cn900019r] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2009] [Accepted: 08/05/2010] [Indexed: 01/06/2023] Open
Abstract
Considerable research effort has focused on the discovery of mitigators that block the toxicity of the β-amyloid peptide (Aβ) by targeting a specific step involved in Aβ fibrillogenesis and subsequent aggregation. Given that aggregation intermediates are hypothesized to be responsible for Aβ toxicity, such compounds could likely prevent or mitigate aggregation, or alternatively cause further association of toxic oligomers into larger nontoxic aggregates. Herein we investigate the effect of modifications of the KLVFF hydrophobic core of Aβ by replacing N- and C-terminal groups with various polar moieties. Several of these terminal modifications were found to disrupt the formation of amyloid fibrils and in some cases induced the disassembly of preformed fibrils. Significantly, mitigators that incorporate MiniPEG polar groups were found to be effective against Aβ(1-40) fibrilligonesis. Previously, we have shown that mitigators incorporating alpha,alpha-disubstituted amino acids (ααAAs) were effective in disrupting fibril formation as well as inducing fibril disassembly. In this work, we further disclose that the number of polar residues (six) and ααAAs (three) in the original mitigator can be reduced without dramatically changing the ability to disrupt Aβ(1-40) fibrillization in vitro.
Collapse
Affiliation(s)
- Cyrus K. Bett
- Department of Chemistry, Louisiana State University, Baton Rouge, Louisiana 70803
| | - Wilson K. Serem
- Department of Chemistry, Louisiana State University, Baton Rouge, Louisiana 70803
| | - Krystal R. Fontenot
- Department of Chemistry, Louisiana State University, Baton Rouge, Louisiana 70803
| | - Robert P. Hammer
- New England Peptide LLC, 65 Zub Lane, Gardner, Massachusetts 01440
| | - Jayne C. Garno
- Department of Chemistry, Louisiana State University, Baton Rouge, Louisiana 70803
| |
Collapse
|
113
|
Bett CK, Ngunjiri JN, Serem WK, Fontenot KR, Hammer RP, McCarley RL, Garno JC. Structure-activity relationships in peptide modulators of β-amyloid protein aggregation: variation in α,α-disubstitution results in altered aggregate size and morphology. ACS Chem Neurosci 2010; 1:608-26. [PMID: 22778850 DOI: 10.1021/cn100045q] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2010] [Accepted: 06/25/2010] [Indexed: 12/20/2022] Open
Abstract
Neuronal cytotoxicity observed in Alzheimer's disease (AD) is linked to the aggregation of β-amyloid peptide (Aβ) into toxic forms. Increasing evidence points to oligomeric materials as the neurotoxic species, not Aβ fibrils; disruption or inhibition of Aβ self-assembly into oligomeric or fibrillar forms remains a viable therapeutic strategy to reduce Aβ neurotoxicity. We describe the synthesis and characterization of amyloid aggregation mitigating peptides (AAMPs) whose structure is based on the Aβ "hydrophobic core" Aβ(17-20), with α,α-disubstituted amino acids (ααAAs) added into this core as potential disrupting agents of fibril self-assembly. The number, positional distribution, and side-chain functionality of ααAAs incorporated into the AAMP sequence were found to influence the resultant aggregate morphology as indicated by ex situ experiments using atomic force microscopy (AFM) and transmission electron microscopy (TEM). For instance, AAMP-5, incorporating a sterically hindered ααAA with a diisobutyl side chain in the core sequence, disrupted Aβ(1-40) fibril formation. However, AAMP-6, with a less sterically hindered ααAA with a dipropyl side chain, altered fibril morphology, producing shorter and larger sized fibrils (compared with those of Aβ(1-40)). Remarkably, ααAA-AAMPs caused disassembly of existing Aβ fibrils to produce either spherical aggregates or protofibrillar structures, suggesting the existence of equilibrium between fibrils and prefibrillar structures.
Collapse
Affiliation(s)
- Cyrus K. Bett
- Department of Chemistry, Louisiana State University, Baton Rouge, Louisiana 70803
| | - Johnpeter N. Ngunjiri
- NanoInk, Inc., Illinois Science & Technology Park, 8025 Lamon Ave, Skokie, Illinois 60077
| | - Wilson K. Serem
- Department of Chemistry, Louisiana State University, Baton Rouge, Louisiana 70803
| | - Krystal R. Fontenot
- Department of Chemistry, Louisiana State University, Baton Rouge, Louisiana 70803
| | - Robert P. Hammer
- New England Peptide LLC, 65 Zub Lane, Gardner, Massachusetts 01440
| | - Robin L. McCarley
- Department of Chemistry, Louisiana State University, Baton Rouge, Louisiana 70803
| | - Jayne C. Garno
- Department of Chemistry, Louisiana State University, Baton Rouge, Louisiana 70803
| |
Collapse
|
114
|
Sciacca MFM, Pappalardo M, Attanasio F, Milardi D, La Rosa C, Grasso DM. Are fibrilgrowth and membrane damage linked processes? An experimental and computational study of IAPP12–18and IAPP21–27peptides. NEW J CHEM 2010. [DOI: 10.1039/b9nj00253g] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
115
|
Ouberai M, Dumy P, Chierici S, Garcia J. Synthesis and Biological Evaluation of Clicked Curcumin and Clicked KLVFFA Conjugates as Inhibitors of β-Amyloid Fibril Formation. Bioconjug Chem 2009; 20:2123-32. [DOI: 10.1021/bc900281b] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Affiliation(s)
- Myriam Ouberai
- Département de Chimie Moléculaire (DCM), UMR 5250, ICMG-FR, Université Joseph Fourier, BP 53, 38041 Grenoble Cedex 9, France
| | - Pascal Dumy
- Département de Chimie Moléculaire (DCM), UMR 5250, ICMG-FR, Université Joseph Fourier, BP 53, 38041 Grenoble Cedex 9, France
| | - Sabine Chierici
- Département de Chimie Moléculaire (DCM), UMR 5250, ICMG-FR, Université Joseph Fourier, BP 53, 38041 Grenoble Cedex 9, France
| | - Julian Garcia
- Département de Chimie Moléculaire (DCM), UMR 5250, ICMG-FR, Université Joseph Fourier, BP 53, 38041 Grenoble Cedex 9, France
| |
Collapse
|
116
|
Dasilva KA, Shaw JE, McLaurin J. Amyloid-beta fibrillogenesis: structural insight and therapeutic intervention. Exp Neurol 2009; 223:311-21. [PMID: 19744483 DOI: 10.1016/j.expneurol.2009.08.032] [Citation(s) in RCA: 94] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2009] [Revised: 08/12/2009] [Accepted: 08/27/2009] [Indexed: 02/02/2023]
Abstract
Structural insight into the conformational changes associated with aggregation and assembly of fibrils has provided a number of targets for therapeutic intervention. Solid-state NMR, hydrogen/deuterium exchange and mutagenesis strategies have been used to probe the secondary and tertiary structure of amyloid fibrils and key intermediates. Rational design of peptide inhibitors directed against key residues important for aggregation and stabilization of fibrils has demonstrated effectiveness at inhibiting fibrillogenesis. Studies on the interaction between Abeta and cell membranes led to the discovery that inositol, the head group of phosphatidylinositol, inhibits fibrillogenesis. As a result, scyllo-inositol is currently in clinical trials for the treatment of AD. Additional small-molecule inhibitors, including polyphenolic compounds such as curcumin, (-)-epigallocatechin gallate (EGCG), and grape seed extract have been shown to attenuate Abeta aggregation through distinct mechanisms, and have shown effectiveness at reducing amyloid levels when administered to transgenic mouse models of AD. Although the results of ongoing clinical trials remain to be seen, these compounds represent the first generation of amyloid-based therapeutics, with the potential to alter the progression of AD and, when used prophylactically, alleviate the deposition of Abeta.
Collapse
Affiliation(s)
- Kevin A Dasilva
- Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada
| | | | | |
Collapse
|
117
|
|
118
|
Rangachari V, Davey ZS, Healy B, Moore BD, Sonoda LK, Cusack B, Maharvi GM, Fauq AH, Rosenberry TL. Rationally designed dehydroalanine (ΔAla)-containing peptides inhibit amyloid-β (Aβ) peptide aggregation. Biopolymers 2009; 91:456-65. [DOI: 10.1002/bip.21151] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
119
|
Chebaro Y, Derreumaux P. Targeting the early steps of Abeta16-22 protofibril disassembly by N-methylated inhibitors: a numerical study. Proteins 2009; 75:442-52. [PMID: 18837034 DOI: 10.1002/prot.22254] [Citation(s) in RCA: 58] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Aggregation of the Abeta1-40/Abeta1-42 peptides is a key factor in Alzheimer's disease. Though the inhibitory effect of N-methylated Abeta16-22 (mAbeta16-22) peptides is well characterized in vitro, there is little information on how they disassemble full-length Abeta fibrils or block fibril formation. Here, we report coarse-grained implicit solvent molecular dynamics (MD) and replica exchange molecular dynamics (REMD) simulations on Abeta16-22 and mAbeta16-22 monomers, and then a preformed six-chain Abeta16-22 bilayer with either four copies of Abeta16-22 or four copies of mAbeta16-22. Our simulations show that the effect of N-methylation on mAbeta16-22 monomer is to reduce the density of compact forms. While 100 ns MD trajectories do not reveal any significant differences between the two ten-chain systems, the REMD simulations totaling 1 micros help understand the first steps of Abeta16-22 protofibril disassembly by N-methylated inhibitors. Notably, we find that mAbeta16-22 preferentially interacts with Abeta16-22 by blocking both beta-sheet extension and lateral association of layers, but also by intercalation of the inhibitors allowing sequestration of Abeta16-22 peptides. This third binding mode is particularly appealing for blocking Abeta fibrillogenesis.
Collapse
Affiliation(s)
- Yassmine Chebaro
- Laboratoire de Biochimie Théorique, UPR 9080 CNRS, Institut de Biologie, Physico Chimique et Université Paris 7 Denis Diderot, 13 rue Pierre et Marie Curie, Paris 75005, France
| | | |
Collapse
|
120
|
Hawkes CA, Ng V, McLaurin J. Small molecule inhibitors of Aβ-aggregation and neurotoxicity. Drug Dev Res 2009. [DOI: 10.1002/ddr.20290] [Citation(s) in RCA: 87] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
|
121
|
van Groen T, Wiesehan K, Funke SA, Kadish I, Nagel-Steger L, Willbold D. Reduction of Alzheimer's disease amyloid plaque load in transgenic mice by D3, A D-enantiomeric peptide identified by mirror image phage display. ChemMedChem 2009; 3:1848-52. [PMID: 19016284 DOI: 10.1002/cmdc.200800273] [Citation(s) in RCA: 99] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- Thomas van Groen
- Dept. Cell Biology, University of Alabama at Birmingham, AL 35294, USA
| | | | | | | | | | | |
Collapse
|
122
|
|
123
|
A Molecular Dynamics Study of the Interaction of d-Peptide Amyloid Inhibitors with Their Target Sequence Reveals a Potential Inhibitory Pharmacophore Conformation. J Mol Biol 2008; 383:266-80. [DOI: 10.1016/j.jmb.2008.07.076] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2008] [Revised: 07/24/2008] [Accepted: 07/25/2008] [Indexed: 11/19/2022]
|
124
|
Camus MS, Dos Santos S, Chandravarkar A, Mandal B, Schmid AW, Tuchscherer G, Mutter M, Lashuel HA. Switch-Peptides: Design and Characterization of Controllable Super-Amyloid-Forming Host-Guest Peptides as Tools for Identifying Anti-Amyloid Agents. Chembiochem 2008; 9:2104-12. [DOI: 10.1002/cbic.200800245] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
125
|
Esteras-Chopo A, Pastor MT, Serrano L, López de la Paz M. New Strategy for the Generation of Specific d-Peptide Amyloid Inhibitors. J Mol Biol 2008; 377:1372-81. [DOI: 10.1016/j.jmb.2008.01.028] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2007] [Revised: 01/02/2008] [Accepted: 01/08/2008] [Indexed: 10/22/2022]
|
126
|
Li Q, Gordon M, Etienne MA, Hammer RP, Morgan D. Contrasting In Vivo Effects of Two Peptide-Based Amyloid-β Protein Aggregation Inhibitors in a Transgenic Mouse Model of Amyloid Deposition. Cell Transplant 2008. [DOI: 10.3727/096368908784423247] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Previous studies have shown that 17,19,21-tri-N-methyl-Aβ16-22 peptide (Aβ16-22m), and a peptide analogue containing α,α-disubsituted amino acids (ααAA) in the hydrophobic core domain of Aβ, termed AMY-1, effectively inhibited full-length Aβ aggregation in vitro. To investigate the amyloid-modifying effects of these agents in vivo, we injected these compounds into the hippocampus of 13-month-old amyloid precursor protein (APP) transgenic mice, a model of amyloid deposition. After 7 days, brain tissues were stained for immunohistochemistry to detect total Aβ and thioflavine-S (THIO-S) to measure Aβ compact plaques. Both diffuse Aβ deposits and compact amyloid plaques were significantly increased when injecting 0.3 nmol Aβ16-22m compared to the PBS vehicle. The amyloid aggregation-modifying peptide AMY-1 showed a slight reduction of Aβ deposition in the injection area at a dose of 0.3 nmol, but neuronal toxicity, measured by Fluoro-Jade and Nissl stains, appeared when higher doses (3 nmol) were tested. Our data indicate that, unlike observations reported in vitro, the Aβ16-22m increased deposition of Aβ in the brain of APP transgenic mice in vivo. Possible explanations for this outcome include unique influences of the brain environment and/or modification of Aβ production or clearance by the administered agent. The AMY-1 peptide showed a trend for reducing Aβ deposits, but led to toxicity at higher doses. These data emphasize the need for evaluating potential Aβ aggregation inhibitors with in vivo models of amyloid deposition before assuming they will have benefit in treating Alzheimer's disease patients.
Collapse
Affiliation(s)
- Qingyou Li
- Alzheimer's Research Laboratory, Department of Molecular Pharmacology and Physiology, University of South Florida, Tampa, FL, USA
| | - Marcia Gordon
- Alzheimer's Research Laboratory, Department of Molecular Pharmacology and Physiology, University of South Florida, Tampa, FL, USA
| | - Marcus A. Etienne
- Department of Chemistry, Louisiana State University, Baton Rouge, LA, USA
| | - Robert P. Hammer
- Department of Chemistry, Louisiana State University, Baton Rouge, LA, USA
| | - Dave Morgan
- Alzheimer's Research Laboratory, Department of Molecular Pharmacology and Physiology, University of South Florida, Tampa, FL, USA
| |
Collapse
|
127
|
Krysmann MJ, Castelletto V, Kelarakis A, Hamley IW, Hule RA, Pochan DJ. Self-Assembly and Hydrogelation of an Amyloid Peptide Fragment. Biochemistry 2008; 47:4597-605. [DOI: 10.1021/bi8000616] [Citation(s) in RCA: 244] [Impact Index Per Article: 15.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Marta J. Krysmann
- Department of Chemistry, University of Reading, Reading RG6 6AD, United Kingdom, and Department of Materials Science and Engineering, Delaware Biotechnology Institute, University of Delaware, Newark, Delaware 19716
| | - Valeria Castelletto
- Department of Chemistry, University of Reading, Reading RG6 6AD, United Kingdom, and Department of Materials Science and Engineering, Delaware Biotechnology Institute, University of Delaware, Newark, Delaware 19716
| | - Antonios Kelarakis
- Department of Chemistry, University of Reading, Reading RG6 6AD, United Kingdom, and Department of Materials Science and Engineering, Delaware Biotechnology Institute, University of Delaware, Newark, Delaware 19716
| | - Ian W. Hamley
- Department of Chemistry, University of Reading, Reading RG6 6AD, United Kingdom, and Department of Materials Science and Engineering, Delaware Biotechnology Institute, University of Delaware, Newark, Delaware 19716
| | - Rohan A. Hule
- Department of Chemistry, University of Reading, Reading RG6 6AD, United Kingdom, and Department of Materials Science and Engineering, Delaware Biotechnology Institute, University of Delaware, Newark, Delaware 19716
| | - Darrin J. Pochan
- Department of Chemistry, University of Reading, Reading RG6 6AD, United Kingdom, and Department of Materials Science and Engineering, Delaware Biotechnology Institute, University of Delaware, Newark, Delaware 19716
| |
Collapse
|
128
|
Abstract
In this article, we support the case that the neurotoxic agent in Alzheimer's disease is a soluble aggregated form of the amyloid beta peptide (Abeta), probably complexed with divalent copper. The structure and chemical properties of the monomeric peptide and its Cu(ii) complex are discussed, as well as what little is known about the oligomeric species. Abeta oligomers are neurotoxic by a variety of mechanisms. They adhere to plasma and intracellular membranes and cause lesions by a combination of radical-initiated lipid peroxidation and formation of ion-permeable pores. In endothelial cells this damage leads to loss of integrity of the blood-brain barrier and loss of blood flow to the brain. At synapses, the oligomers close neuronal insulin receptors, mirroring the effects of Type II diabetes. In intracellular membranes, the most damaging effect is loss of calcium homeostasis. The oligomers also bind to a variety of substances, mostly with deleterious effects. Binding to cholesterol is accompanied by its oxidation to products that are themselves neurotoxic. Possibly most damaging is the binding to tau, and to several kinases, that results in the hyperphosphorylation of the tau and abrogation of its microtubule-supporting role in maintaining axon structure, leading to diseased synapses and ultimately the death of neurons. Several strategies are presented and discussed for the development of compounds that prevent the oligomerization of Abeta into the neurotoxic species.
Collapse
Affiliation(s)
- Arvi Rauk
- Department of Chemistry, University of Calgary, Calgary, AB T2N 1N4, Canada
| |
Collapse
|
129
|
Abstract
The fibrillization of peptides is relevant to many diseases based on the deposition of amyloids. The formation of fibrils is being intensively studied, especially in terms of nanotechnology applications, where fibrillar peptide hydrogels are used for cell scaffolds, as supports for functional and responsive biomaterials, biosensors, and nanowires. This Review is concerned with fundamental aspects of the self-assembly of peptides into fibrils, and discusses both natural amyloid-forming peptides and synthetic materials, including peptide fragments, copolymers, and amphiphiles.
Collapse
Affiliation(s)
- Ian W Hamley
- Department of Chemistry, University of Reading, Reading, Berkshire RG6 6AD, UK.
| |
Collapse
|
130
|
|
131
|
Krysmann MJ, Castelletto V, Hamley IW. Fibrillisation of hydrophobically modified amyloid peptide fragments in an organic solvent. SOFT MATTER 2007; 3:1401-1406. [PMID: 32900120 DOI: 10.1039/b709889h] [Citation(s) in RCA: 75] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/02/2023]
Abstract
The self-assembly of a hydrophobically modified fragment of the amyloid β (Aβ) peptide has been studied in methanol. The peptide FFKLVFF is based on Aβ(16-20) extended at the N terminus by two phenylalanine residues. The formation of amyloid-type fibrils is confirmed by Congo Red staining, thioflavin T fluorescence and circular dichroism experiments. FTIR points to the formation of β-sheet structures in solution and in dried films and suggests that aggregation occurs at low concentration and is not strongly affected by further increase in concentration, i.e. the peptide is a strong fibril-former in methanol. UV fluorescence experiments on unstained peptide and CD point to the importance of aromatic interactions between phenylalanine groups in driving aggregation into β-sheets. The CD spectrum differs from that usually observed for β-sheet assemblies formed by larger peptides or proteins and this is discussed for solutions in methanol and also trifluoroethanol. The fibril structure is imaged by transmission electron microscopy and scanning electron microscopy on dried samples and is confirmed by small-angle X-ray scattering experiments in solution.
Collapse
Affiliation(s)
- M J Krysmann
- Dept of Chemistry, The University of Reading, Reading, UKRG6 6AD.
| | - V Castelletto
- Dept of Chemistry, The University of Reading, Reading, UKRG6 6AD.
| | - I W Hamley
- Dept of Chemistry, The University of Reading, Reading, UKRG6 6AD.
| |
Collapse
|
132
|
Chafekar SM, Malda H, Merkx M, Meijer EW, Viertl D, Lashuel HA, Baas F, Scheper W. Branched KLVFF Tetramers Strongly Potentiate Inhibition of β-Amyloid Aggregation. Chembiochem 2007; 8:1857-64. [PMID: 17763487 DOI: 10.1002/cbic.200700338] [Citation(s) in RCA: 106] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
The key pathogenic event in the onset of Alzheimer's disease (AD) is the aggregation of beta-amyloid (Abeta) peptides into toxic aggregates. Molecules that interfere with this process might act as therapeutic agents for the treatment of AD. The amino acid residues 16-20 (KLVFF) are known to be essential for the aggregation of Abeta. In this study, we have used a first-generation dendrimer as a scaffold for the multivalent display of the KLVFF peptide. The effect of four KLVFF peptides attached to the dendrimer (K(4)) on Abeta aggregation was compared to the effect of monomeric KLVFF (K(1)). Our data show that K(4) very effectively inhibits the aggregation of low-molecular-weight and protofibrillar Abeta(1-42) into fibrils, in a concentration-dependent manner, and much more potently than K(1). Moreover, we show that K(4) can lead to the disassembly of existing aggregates. Our data lead us to propose that conjugates that bear multiple copies of KLVFF might be useful as therapeutic agents for the treatment of Alzheimer's disease.
Collapse
Affiliation(s)
- Sidhartha M Chafekar
- Neurogenetics Laboratory, Academic Medical Center, P.O. Box 22660, 1100 DD Amsterdam, The Netherlands
| | | | | | | | | | | | | | | |
Collapse
|
133
|
Kwon YE, Park JY, No KT, Shin JH, Lee SK, Eun JS, Yang JH, Shin TY, Kim DK, Chae BS, Leem JY, Kim KH. Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Aβ1–42 aggregation for Alzheimer’s disease therapeutics. Bioorg Med Chem 2007; 15:6596-607. [PMID: 17681794 DOI: 10.1016/j.bmc.2007.07.003] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2007] [Revised: 06/30/2007] [Accepted: 07/06/2007] [Indexed: 11/16/2022]
Abstract
With the goal of developing Alzheimer's disease therapeutics, we have designed and synthesized new piperidine derivatives having dual action of acetylcholinesterase (AChE) and beta-amyloid peptide (Abeta) aggregation inhibition. For binding with the catalytic site of AChE, an ester with aromatic group was designed, and for the peripheral site, another aromatic group was considered. And for intercalating amyloid-beta oligomerization, long and linear conformation with a lipophilic group was considered. The synthetic methods employed for the structure with dual action depended on alcohols with an aromatic ring and the substituted benzoic acids, which are esterificated in the last step of the synthetic pathway. We screened these new derivatives through inhibition tests of acetylcholinesterase, butyrylcholinesterase (BChE), and Abeta(1-42) peptide aggregation, AChE-induced Abeta(1-42) aggregation. Our results displayed that compound 12 showed the best inhibitory potency and selectivity of AChE, and 29 showed the highest selectivity of BChE inhibition. Compounds 15 and 12 had inhibitory activities against Abeta(1-42) aggregation and AChE-induced Abeta aggregation. In the docking model, we confirmed that 4-chlorobenzene of 12 plays the parallel pi-pi stacking against the indole ring of Trp84 in the bottom gorge of AChE. Because the benzyhydryl moiety of 12 covered the peripheral site of AChE in a funnel-like shape, 12 showed good inhibitory potency against AChE and could inhibit AChE-induced Abeta(1-42) peptide aggregation.
Collapse
Affiliation(s)
- Young Ee Kwon
- College of Pharmacy, Woosuk University, Jeonbuk, Republic of Korea.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
134
|
Matsuzaki K, Noguch T, Wakabayashi M, Ikeda K, Okada T, Ohashi Y, Hoshino M, Naiki H. Inhibitors of amyloid β-protein aggregation mediated by GM1-containing raft-like membranes. BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES 2007; 1768:122-30. [PMID: 17069749 DOI: 10.1016/j.bbamem.2006.09.014] [Citation(s) in RCA: 65] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/18/2006] [Revised: 08/11/2006] [Accepted: 09/05/2006] [Indexed: 11/16/2022]
Abstract
The aggregation (fibril formation) of amyloid beta-protein (Abeta) is considered to be a crucial step in the etiology of Alzheimer's disease (AD). The inhibition of Abeta aggregation and/or decomposition of fibrils formed in aqueous solution by small compounds have been studied extensively for the prevention and treatment of AD. However, recent studies suggest that Abeta aggregation also occurs in lipid rafts mediated by a cluster of monosialoganglioside GM1. This study examined the effects of representative compounds on Abeta aggregation and fibril destabilization in the presence of GM1-containing raft-like liposomes. Among the compounds tested, nordihydroguaiaretic acid (NDGA), rifampicin (RIF), tannic acid (TA), and quercetin (QUE) showed strong fibrillization inhibitory activity. NDGA and RIF inhibited the binding of Abeta to GM1 liposomes by competitively binding to the membranes and/or direct interaction with Abeta in solution, thus at least partly preventing fibrils from forming. Coincubation of Abeta with NDGA, RIF, and QUE in the presence of GM1 liposomes resulted in elongate particles, whereas the presence of TA yielded protofibrillar structures. TA and RIF also destabilized fibrils. The most potent NDGA prevented Abeta-induced toxicity in PC12 cells by inhibiting Abeta accumulation. Furthermore, a comparison of the inhibitory effects of various compounds between aqueous-phase and GM1-mediated aggregation of Abeta suggested that the two aggregation processes are not identical.
Collapse
Affiliation(s)
- Katsumi Matsuzaki
- Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
135
|
Sato T, Kienlen-Campard P, Ahmed M, Liu W, Li H, Elliott JI, Aimoto S, Constantinescu SN, Octave JN, Smith SO. Inhibitors of amyloid toxicity based on beta-sheet packing of Abeta40 and Abeta42. Biochemistry 2006; 45:5503-16. [PMID: 16634632 PMCID: PMC2593882 DOI: 10.1021/bi052485f] [Citation(s) in RCA: 160] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Amyloid fibrils associated with Alzheimer's disease and a wide range of other neurodegenerative diseases have a cross beta-sheet structure, where main chain hydrogen bonding occurs between beta-strands in the direction of the fibril axis. The surface of the beta-sheet has pronounced ridges and grooves when the individual beta-strands have a parallel orientation and the amino acids are in-register with one another. Here we show that in Abeta amyloid fibrils, Met35 packs against Gly33 in the C-terminus of Abeta40 and against Gly37 in the C-terminus of Abeta42. These packing interactions suggest that the protofilament subunits are displaced relative to one another in the Abeta40 and Abeta42 fibril structures. We take advantage of this corrugated structure to design a new class of inhibitors that prevent fibril formation by placing alternating glycine and aromatic residues on one face of a beta-strand. We show that peptide inhibitors based on a GxFxGxF framework disrupt sheet-to-sheet packing and inhibit the formation of mature Abeta fibrils as assayed by thioflavin T fluorescence, electron microscopy, and solid-state NMR spectroscopy. The alternating large and small amino acids in the GxFxGxF sequence are complementary to the corresponding amino acids in the IxGxMxG motif found in the C-terminal sequence of Abeta40 and Abeta42. Importantly, the designed peptide inhibitors significantly reduce the toxicity induced by Abeta42 on cultured rat cortical neurons.
Collapse
Affiliation(s)
- Takeshi Sato
- Department of Biochemistry and Cell Biology, Center for Structural Biology, Stony Brook University, Stony Brook, NY 11794-5215
| | - Pascal Kienlen-Campard
- Experimental Pharmacology Unit, Université Catholique de Louvain, Brussels 1200, Belgium
| | - Mahiuddin Ahmed
- Department of Biochemistry and Cell Biology, Center for Structural Biology, Stony Brook University, Stony Brook, NY 11794-5215
| | - Wei Liu
- Department of Biochemistry and Cell Biology, Center for Structural Biology, Stony Brook University, Stony Brook, NY 11794-5215
| | - Huilin Li
- Department of Biology, Brookhaven National Laboratory, Upton, NY
| | - James I. Elliott
- Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, CT 06520
| | - Saburo Aimoto
- Institute for Protein Research, Osaka University, 3-2 Yamadaoka, Suita, Osaka 565-0871, Japan
| | - Stefan N. Constantinescu
- Ludwig Institute for Cancer Research, Bruxelles 1200, Belgium. Christian de Duve Institute of Cellular Pathology, MEXP Unit, Université Catholique de Louvain, Brussels 1200, Belgium
| | - Jean-Noel Octave
- Experimental Pharmacology Unit, Université Catholique de Louvain, Brussels 1200, Belgium
| | - Steven O. Smith
- Department of Biochemistry and Cell Biology, Center for Structural Biology, Stony Brook University, Stony Brook, NY 11794-5215
- Address correspondence to: Steven O. Smith, Department of Biochemistry and Cell Biology, Center for Structural Biology, Stony Brook University, Stony Brook, NY 11794-5215, Tel. 631 632-1210; Fax. 631-632-8575.
| |
Collapse
|
136
|
Gazit E. Mechanisms of amyloid fibril self-assembly and inhibition. Model short peptides as a key research tool. FEBS J 2006; 272:5971-8. [PMID: 16302962 DOI: 10.1111/j.1742-4658.2005.05022.x] [Citation(s) in RCA: 198] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The formation of amyloid fibrils is associated with various human medical disorders of unrelated origin. Recent research indicates that self-assembled amyloid fibrils are also involved in physiological processes in several micro-organisms. Yet, the molecular basis for the recognition and self-assembly processes mediating the formation of such structures from their soluble protein precursors is not fully understood. Short peptide models have provided novel insight into the mechanistic issues of amyloid formation, revealing that very short peptides (as short as a tetrapeptide) contain all the necessary molecular information for forming typical amyloid fibrils. A careful analysis of short peptides has not only facilitated the identification of molecular recognition modules that promote the interaction and self-assembly of fibrils but also revealed that aromatic interactions are important in many cases of amyloid formation. The realization of the role of aromatic moieties in fibril formation is currently being used to develop novel inhibitors that can serve as therapeutic agents to treat amyloid-associated disorders.
Collapse
Affiliation(s)
- Ehud Gazit
- Department of Molecular Microbiology and Biotechnology, Tel Aviv University, Tel Aviv, Israel.
| |
Collapse
|
137
|
Abstract
This review considers the design, synthesis, and mechanistic assessment of peptide-based fibrillogenesis inhibitors, mainly focusing on beta-amyloid, but generalizable to other aggregating proteins and peptides. In spite of revision of the "amyloid hypothesis," the investigation and development of fibrillogenesis inhibitors remain important scientific and therapeutic goals for at least three reasons. First, it is still premature to dismiss fibrils altogether as sources of cytotoxicity. Second, a "fibrillogenesis inhibitor" is typically identified experimentally as such, but these compounds may also bind to intermediates in the fibrillogenesis pathway and have hard-to-predict consequences, including improved clearance of more cytotoxic soluble oligomers. Third, inhibitors are valuable structural probes, as the entire field of enzymology attests. Screening procedures for selection of random inhibitory sequences are briefly considered, but the bulk of the review concentrates on rationally designed fibrillogenesis inhibitors. Among these are internal segments of fibril-forming peptides, amino acid substitutions and side chain modifications of fibrillogenic domains, insertion of prolines into or adjacent to fibrillogenic domains, modification of peptide termini, modification of peptide backbone atoms (including N-methylation), peptide cyclization, use of D-amino acids in fibrillogenic domains, and nonpeptidic beta-sheet mimics. Finally, we consider methods of assaying fibrillogenesis inhibitors, including pitfalls in these assays. We consider binding of inhibitor peptides to their targets, but because this is a specific application of the more general and much larger problem of assessing protein-protein interactions, this topic is covered only briefly. Finally, we consider potential applications of inhibitor peptides to therapeutic strategies.
Collapse
|
138
|
Mihara H, Matsumura S, Takahashi T. Construction and Control of Self-Assembly of Amyloid and Fibrous Peptides. BULLETIN OF THE CHEMICAL SOCIETY OF JAPAN 2005. [DOI: 10.1246/bcsj.78.572] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
139
|
Elimova E, Kisilevsky R, Szarek WA, Ancsin JB. Amyloidogenesis recapitulated in cell culture: a peptide inhibitor provides direct evidence for the role of heparan sulfate and suggests a new treatment strategy. FASEB J 2004; 18:1749-51. [PMID: 15345688 DOI: 10.1096/fj.03-1436fje] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
To date 22 different polypeptides, including Abeta in Alzheimer's disease and PrP(Sc) in prion disorders, are known to re-fold and assemble into highly organized fibrils, which associate with heparan sulfate (HS) proteoglycans to form tissue deposits called amyloid. Mononuclear phagocytes have long been thought to be involved in this process, and we describe a monocytic cell culture system that can transform the acute-phase protein serum amyloid A (SAA1.1) into AA-amyloid and appears to recapitulate all the main features of amyloidogenesis observed in vivo. These features in common include nucleation-dependent kinetics, identical proteolytic processing of SAA1.1, and co-deposition of HS with the fibrils. Heparin and polyvinylsulfonate previously reported to block AA-amyloidogenesis in mice are also effective inhibitors in this cell culture model. Furthermore, a synthetic peptide (27-mer) corresponding to a HS binding site of SAA, blocks amyloid deposition at a concentration that is several-orders-of-magnitude lower than any other peptide-based inhibitor previously reported. The 27-mer's inhibitory activity may target the amyloidogenic pathway specifically as it does not interfere with the binding of SAA to monocytes. These data provide direct evidence that SAA1.1:HS interactions are a critical step in AA-amyloidogenesis and suggest a novel treatment strategy for other amyloidoses.
Collapse
Affiliation(s)
- Elena Elimova
- Department of Biochemistry, Queen's University, Kingston, Ontario, Canada
| | | | | | | |
Collapse
|
140
|
Yu H, Daura X, van Gunsteren WF. Molecular dynamics simulations of peptides containing an unnatural amino acid: dimerization, folding, and protein binding. Proteins 2004; 54:116-27. [PMID: 14705028 DOI: 10.1002/prot.10502] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
We have performed molecular dynamics (MD) simulations to study the dimerization, folding, and binding to a protein of peptides containing an unnatural amino acid. NMR studies have shown that the substitution of one residue in a tripeptide beta-strand by the unnatural amino acid Hao (5-HO2CCONH-2-MeO-C6H3-CO-NHNH2) modifies the conformational flexibility of the beta-strand and the hydrogen-bonding properties of its two edges: The number of hydrogen-bond donors and acceptors increases at one edge, whereas at the other, they are sterically hindered. In simulations in chloroform, the Hao-containing peptide 9 (i-PrCO-Phe-Hao-Val-NHBu) forms a beta-sheet-like hydrogen-bonded dimer, in good agreement with the available experimental data. Addition of methanol to the solution induces instability of this beta-sheet, as confirmed by the experiments. MD simulations also reproduce the folding of the synthetic peptide 1a (i-PrCO-Hao-Ut-Phe-Ile-Leu-NHMe) into a beta-hairpin-like structure in chloroform. Finally, the Hao-containing peptide, Ac-Ala-Hao-Ala-NHMe, is shown to form a stable complex with the Ras analogue, Rap1 A, in water at room temperature. Together with the available experimental data, these simulation studies indicate that Hao-containing peptides may serve as inhibitors of beta-sheet interactions between proteins.
Collapse
Affiliation(s)
- Haibo Yu
- Laboratory of Physical Chemistry, Swiss Federal Institute of Technology Zurich, ETH Hönggerberg, 8093 Zürich, Switzerland
| | | | | |
Collapse
|
141
|
Scrocchi LA, Chen Y, Wang F, Han K, Ha K, Wu L, Fraser PE. Inhibitors of islet amyloid polypeptide fibrillogenesis, and the treatment of type-2 diabetes. Int J Pept Res Ther 2003. [DOI: 10.1007/s10989-004-2423-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
142
|
Yamashita T, Takahashi Y, Takahashi T, Mihara H. Inhibition of peptide amyloid formation by cationic peptides with homologous sequences. Bioorg Med Chem Lett 2003; 13:4051-4. [PMID: 14592506 DOI: 10.1016/j.bmcl.2003.08.077] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
We have studied the model peptides that undergo self-initiated structural transition from alpha-helix to beta-sheet and self-assembling into amyloid fibrils. We here constructed an inhibition system of amyloid formation utilizing homologous recognition and assembly of peptides with increased solubility. Among 20 peptides with homologous sequences examined here, cationic peptides showed the stronger inhibition ability against the amyloid formation of a model peptide.
Collapse
Affiliation(s)
- Taro Yamashita
- Department of Bioengineering, Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology, Nagatsuta, Midori-ku, Yokohama 226-8501, Japan
| | | | | | | |
Collapse
|
143
|
Moss MA, Nichols MR, Reed DK, Hoh JH, Rosenberry TL. The Peptide KLVFF-K6Promotes β-Amyloid(1–40) Protofibril Growth by Association but Does Not Alter Protofibril Effects on Cellular Reduction of 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Bromide (MTT). Mol Pharmacol 2003; 64:1160-8. [PMID: 14573766 DOI: 10.1124/mol.64.5.1160] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
The peptide KLVFF-K6 was observed by Lowe et al. to simultaneously enhance amyloid beta-protein (Abeta) fibrillogenesis and decrease cellular toxicity, as measured in a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction assay. It was postulated that accelerated Abeta aggregation and precipitation induced by KLVFF-K6 may lead to an increase in less toxic insoluble fibrils at the expense of more toxic soluble protofibrils. In a previous study, we distinguished between two modes of protofibril growth: elongation by monomer deposition and direct protofibril-protofibril association. These growth mechanisms could be resolved by varying Abeta monomer and NaCl concentrations. Using assays designed to isolate these distinct modes of protofibril growth, we report here that larger Abeta aggregates formed in the presence of KLVFF-K6 resulted from enhanced protofibril association. 3H-Radiomethylated KLVFF-K6 bound to associated protofibrils with an apparent Kd of 180 nM, and concentrations of free [3H]KLVFF-K6 in this range were sufficient to convert soluble protofibrils to sedimentable fibrils. However, promotion of Abeta protofibril association by KLVFF-K6 had no effect on Abeta-induced decreases in cellular MTT reduction. Therefore, our data do not support the proposal that insoluble fibrils formed with KLVFF-K6 are less toxic than soluble protofibrils. KLVFF-K6 did not alter rates of protofibril elongation by monomer deposition. In contrast, when added to Abeta monomers isolated with the use of size-exclusion chromatography, KLVFF-K6 inhibited fibrillogenesis, as measured by thioflavin T fluorescence, and this inhibition was paralleled by a failure to alter cellular MTT reduction.
Collapse
Affiliation(s)
- Melissa A Moss
- Department of Neurosciences, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA
| | | | | | | | | |
Collapse
|
144
|
Kim JR, Gibson TJ, Murphy RM. Targeted control of kinetics of beta-amyloid self-association by surface tension-modifying peptides. J Biol Chem 2003; 278:40730-5. [PMID: 12917437 DOI: 10.1074/jbc.m305466200] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Brain tissue from Alzheimer's patients contains extracellular senile plaques composed primarily of deposits of fibrillar aggregates of beta-amyloid peptide. beta-Amyloid aggregation is postulated to be a major factor in the onset of this neurodegenerative disease. Recently proposed is the hypothesis that oligomeric intermediates, rather than fully formed insoluble fibrils, are cytotoxic. Previously, we reported the discovery of peptides that accelerate beta-amyloid aggregation yet inhibit toxicity in vitro, in support of this hypothesis. These peptides contain two domains: a recognition element designed to bind to beta-amyloid and a disrupting element that alters beta-amyloid aggregation kinetics. Here we show that the aggregation rate-enhancing activity of the disrupting element correlates strongly with its ability to increase surface tension of aqueous solutions. Using the Hofmeister series as a guide, we designed a novel peptide with terminal side-chain trimethylammonium groups in the disrupting domain. The derivatized peptide greatly increased solvent surface tension and accelerated beta-amyloid aggregation kinetics by severalfold. Equivalent increases in surface tension in the absence of a recognition domain had no effect on beta-amyloid aggregation. These results suggest a novel strategy for targeting localized changes in interfacial energy to specific proteins, as a way to selectively alter protein folding, stability, and aggregation.
Collapse
Affiliation(s)
- Jin Ryoun Kim
- Department of Chemical Engineering, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | | | | |
Collapse
|
145
|
Chalifour RJ, McLaughlin RW, Lavoie L, Morissette C, Tremblay N, Boulé M, Sarazin P, Stéa D, Lacombe D, Tremblay P, Gervais F. Stereoselective interactions of peptide inhibitors with the beta-amyloid peptide. J Biol Chem 2003; 278:34874-81. [PMID: 12840031 DOI: 10.1074/jbc.m212694200] [Citation(s) in RCA: 123] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Residues 16-20 of the beta-amyloid peptide (A beta) function as a self-recognition element during A beta assembly into fibers. Peptides containing this motif retain the ability to interact with A beta and, in some cases, potently inhibit its assembly. Replacing L- with D-amino acids could stabilize such peptides and permit their evaluation as therapeutic agents for Alzheimer's disease. Here we have assessed the effect that such a chiral reversal has on inhibitory potency. D-enantiomers of five peptides, KLVFFA, KKLVFFA, KFVFFA, KIVFFA, and KVVFFA, were unexpectedly more active as inhibitors in an in vitro fibrillogenesis assay. Circular dichroism showed that D-KLVFFA more effectively prevented A beta adopting the beta-sheet secondary structure correlated with fibrillogenesis. Electron microscopy showed that fiber formation was also more strongly inhibited by D-KLVFFA. Heterochiral inhibition was confirmed using D-A beta, on the principle that enantiomeric proteins exhibit reciprocal chiral biochemical interactions. With D-Abeta, L-KLVFFA was the more potent inhibitor, rather than d-KLVFFA. Most significantly, D-peptides were more potent at reducing the toxicity of both A beta1-40 and A beta 1-42 toward neuronal cells in culture. This unforeseen heterochiral stereoselectivity of A beta for D-peptide inhibitors should be considered during future design of peptide-based inhibitors of A beta neurotoxicity and fibrillogenesis.
Collapse
|
146
|
Lin SY, Chu HL. Fourier transform infrared spectroscopy used to evidence the prevention of beta-sheet formation of amyloid beta(1-40) peptide by a short amyloid fragment. Int J Biol Macromol 2003; 32:173-7. [PMID: 12957314 DOI: 10.1016/s0141-8130(03)00051-5] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Reflectance Fourier transform infrared (FT-IR) microspectroscopy was applied to study the prevention of beta-sheet formation of amyloid beta (Abeta)(1-40) peptide by co-incubation with a hexapeptide containing a KLVFF sequence (Abeta(15-20) fragment). Second-derivative spectral analysis was used to locate the position of the overlapping components of the amide I band of Abeta peptide and assigned them to different secondary components. The result indicates that each intact sample of Abeta(15-20) fragment or Abeta(1-40) peptide previously incubated in distilled water at 37 degrees C transformed their secondary structure from 1649 (1651) or 1653cm(-1) to 1624cm(-1), suggesting the transformation from alpha-helix and/or random coil structures to beta-sheet structure. By co-incubating both samples with different molar ratio in distilled water at 37 degrees C, the structural transformation was not found for Abeta(1-40) peptide after 24h-incubation. But the beta-sheet formation of Abeta(1-40) peptide after 48h-incubation was evidenced from the appearance of the IR peak at 1626cm(-1) by adding a little amount of Abeta(15-20) fragment. There was no beta-sheet formation of Abeta(1-40) peptide after addition with much amount of Abeta(15-20) fragment, however, suggesting the higher amount of Abeta(15-20) fragment used might inhibit the beta-sheet formation of Abeta(1-40) peptide. The more Abeta(15-20) fragment used made the more stable structure of Abeta(1-40) peptide and the less beta-sheet formation of Abeta(1-40) peptide. The study indicates that the reflectance FT-IR microspectroscopy can easily evidence the prevention of beta-sheet formation of Abeta(1-40) peptide by a short amyloid fragment.
Collapse
Affiliation(s)
- Shan-Yang Lin
- Biopharmaceutics Laboratory, Department of Medical Research and Education, Veterans General Hospital-Taipei, Shih-Pai, Taipei, Taiwan, ROC.
| | | |
Collapse
|
147
|
Scrocchi LA, Chen Y, Wang F, Han K, Ha K, Wu L, Fraser PE. Inhibitors of islet amyloid polypeptide fibrillogenesis, and the treatment of type-2 diabetes. ACTA ACUST UNITED AC 2003. [DOI: 10.1007/bf02442587] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
148
|
Abstract
Numerous diseases have been linked to a common pathogenic process called amyloidosis, whereby proteins or peptides clump together in the brain or body to form toxic soluble oligomers and/or insoluble fibres. An attractive strategy to develop therapies for these diseases is therefore to inhibit or reverse protein/peptide aggregation. A diverse range of small organic ligands have been found to act as aggregation inhibitors. Alternatively, the wild-type peptide can be derivatised so that it still binds to the amyloid target, but prevents further aggregation. This can be achieved by adding a bulky group or charged amino acid to either end of the peptide, or by incorporating proline residues or N-methylated amide groups.
Collapse
Affiliation(s)
- Jody M Mason
- Department of Biomolecular Sciences, UMIST, PO Box 88, Manchester M60 1QD, UK
| | | | | | | |
Collapse
|
149
|
Scrocchi LA, Ha K, Chen Y, Wu L, Wang F, Fraser PE. Identification of minimal peptide sequences in the (8-20) domain of human islet amyloid polypeptide involved in fibrillogenesis. J Struct Biol 2003; 141:218-27. [PMID: 12648568 DOI: 10.1016/s1047-8477(02)00630-5] [Citation(s) in RCA: 68] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
We have examined a series of overlapping peptide fragments from the 8-20 region of human islet amyloid polypeptide (IAPP) with the objective of defining the smallest fibril-forming domain. Peptide fragments corresponding to LANFLV (residues 12-17) and FLVHSS (residues 15-20) were strong enhancers of beta-sheet transition and fibril formation. Negative stain electron microscopy illustrated the ability of these peptide fragments to form fibrils independently when incubated alone in solution. Circular dichroism analysis revealed that when full-length human IAPP was incubated in the presence of these two fragments, fibrillogenesis was accelerated. While the two fragments, LANFLV and FLVHSS, were able to enhance the recruitment of additional IAPP molecules during fibril formation, the "seeding" activity of these peptides had no effect on altering IAPP-induced cytotoxcity as determined by cell culture studies. Therefore, this study has identified two internal IAPP peptide fragments within the 8-20 domain that may have a role in enhancing the folding and aggregation of human IAPP. These fragments are the smallest sequences identified, within the 8-20 region of hIAPP, that can independently form fibrils, and that can interact with IAPP to assemble into fibrils with characteristics similar as those formed by human IAPP alone.
Collapse
Affiliation(s)
- Louise A Scrocchi
- Centre for Research in Neurodegenerative Diseases, University of Toronto, Tanz Neuroscience Building, 6 Queen's Park Crescent West, Ont., M5S 3H2, Toronto, Canada.
| | | | | | | | | | | |
Collapse
|
150
|
Akikusa S, Watanabe KI, Horikawa E, Nakamura K, Kodaka M, Okuno H, Konakahara T. Practical assay and molecular mechanism of aggregation inhibitors of beta-amyloid. THE JOURNAL OF PEPTIDE RESEARCH : OFFICIAL JOURNAL OF THE AMERICAN PEPTIDE SOCIETY 2003; 61:1-6. [PMID: 12472843 DOI: 10.1034/j.1399-3011.2003.21028.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Beta-Amyloid peptide (Abeta) is the main protein component of neuritic plaques in the brain of patients of Alzheimer's disease (AD), and its neurotoxicity would be exposed by the formation of aggregates. The aggregation inhibitors composed of an Abeta recognition element (KLVFF) and a hydrophilic moiety are evaluated by a novel fluorescence assay. These compounds inhibit growth of the model aggregates on the KLVFF immobilized surface. In addition, some compounds also possess disrupting activities of preformed aggregates. These compounds could be a key candidate for therapeutic drugs for AD by their novel molecular mechanisms.
Collapse
Affiliation(s)
- S Akikusa
- National Institute of Advanced Industrial Science and Technology (AIST), Ibaraki, Japan
| | | | | | | | | | | | | |
Collapse
|